Puliyan, a medical aesthetics company based in Nanjing, has completed a $50 million Series C funding round led by Mirae Asset China, marking a significant investment in the regenerative skincare sector. The financing attracted participation from existing backers Alwin Capital and Huatai Zijin Investment, underscoring continued confidence in the startup’s approach to skin health.
The six-year-old company has carved out a specialized niche in regenerative aesthetics, a field that emphasizes enhancing the body’s natural repair mechanisms rather than providing short-term cosmetic solutions. This methodology represents a departure from traditional skincare approaches that focus primarily on surface-level improvements.
Regulatory Approvals Drive Market Access
Puliyan has secured two Class III medical device approvals from China’s National Medical Products Administration, the country’s highest level of medical device certification. These approvals encompass Sculptra injections designed to stimulate collagen production and thread lifting procedures that provide facial elevation through minimally invasive techniques.
The regulatory clearances provide Puliyan with access to medical treatment applications, expanding beyond traditional cosmetic markets. Both approved treatments target underlying skin structure rather than surface appearance, aligning with the company’s regenerative philosophy.
Manufacturing Capabilities and Expansion Plans
The company operates from a fully automated production facility spanning more than 4,000 square meters, providing the infrastructure necessary for scaled manufacturing. The new capital will fund development of additional regenerative skincare products, with emphasis on natural and recycled material composition.
Geographic expansion represents a key component of Puliyan’s growth strategy, with plans to extend medical treatment applications across China and international markets. The company aims to broaden clinical adoption of its regenerative technologies through enhanced product development and market penetration.
Strategic Partnership with Mirae Asset
Jim Wang, CEO of Mirae Asset China, outlined the investment rationale, stating the firm “will support Puliyan in improving its products and expanding into clinical use” The partnership extends beyond financial backing to include strategic guidance for international expansion and product enhancement initiatives.
Jim Wang emphasized the broader industry context, noting “Our support will help Puliyan grow internationally, as part of a larger move in China’s beauty industry toward regenerative treatments” This positioning reflects evolving consumer preferences toward long-term skin health solutions over temporary cosmetic interventions.
Investor Profile and Market Context
Mirae Asset Financial Group, established in 1997 and headquartered in Seoul, manages over $620 billion in global assets, including more than $15.8 billion in equity investments as of June 2025. The South Korean financial conglomerate’s investment through its China division signals institutional confidence in the Chinese medical aesthetics market.
The funding round occurs amid growing interest in regenerative medicine applications across various therapeutic areas. Puliyan’s focus on natural healing processes aligns with broader healthcare trends emphasizing preventive and restorative approaches over reactive treatments.
Technology and Treatment Approach
The company’s regenerative aesthetics platform centers on stimulating biological processes that improve skin health over extended periods. This approach contrasts with conventional cosmetic treatments that provide immediate but temporary results, instead focusing on gradual improvements through enhanced cellular function.
Puliyan’s approved treatments work by activating collagen synthesis and providing structural support through biocompatible materials. The thread lifting technology offers facial rejuvenation through minimally invasive procedures, while Sculptra injections promote natural collagen rebuilding over several months.
The emphasis on natural and recycled materials in future product development reflects growing consumer demand for sustainable healthcare solutions. This focus may provide competitive advantages as regulatory frameworks increasingly emphasize environmental considerations in medical device approval processes.